Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 2 IN DEXTROSE 5 versus SCANDONEST PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 2 IN DEXTROSE 5 versus SCANDONEST PLAIN.
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% vs SCANDONEST PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.
Scandonest Plain (mepivacaine) is an amide-type local anesthetic that stabilizes neuronal membranes by binding to voltage-gated sodium channels, inhibiting sodium influx and blocking nerve impulse conduction.
1-1.5 mg/kg IV bolus over 2-3 minutes, followed by continuous IV infusion of 1-4 mg/min for ventricular arrhythmias; maximum 3 mg/kg (or 200-300 mg) over 1 hour.
Dental infiltration: 1-2 mL (20-40 mg mepivacaine). Nerve block: 2-4 mL (40-80 mg). Max dose: 400 mg (approx 7 mg/kg). Do not repeat within 2 hours.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (adults); prolonged in heart failure (up to 4-6 hours) or hepatic impairment (up to 5-7 hours).
Terminal elimination half-life: 1.9–3.2 hours in healthy adults; prolonged to 6–8 hours in hepatic impairment or severe renal disease; clinically meaningful for redosing intervals.
Renal: ~90% as metabolites and <10% unchanged. Biliary/fecal: minor (<1%).
Renal excretion of unchanged drug and metabolites accounts for >95% of elimination; approximately 80% as unchanged mepivacaine and 15% as N-demethylated metabolites; biliary/fecal excretion minimal (<5%).
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic